Internal appointment at UK MHRA as Ian Hudson named new chief exec
This article was originally published in Scrip
Ian Hudson has been named the new head of the UK Medicines and Healthcare Products Regulatory Agency. Dr Hudson, currently the MHRA’s licensing director, will succeed Professor Sir Kent Woods when the latter steps down in September after almost 10 years as chief executive of the agency. Dr Hudson is well-known in regulatory and industry circles. He is the UK delegate to the European Medicines Agency’s Committee on Human Medicinal Products (CHMP) and has been the committee’s vice-chairman since October 2012.
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.